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Even after the publication of persuasive
evidence linking lung cancer to tobacco
smoking (1), some investigators questioned
that the evidence incriminated smoking as
a cause ofcancer in humans. In particular,
R.A. Fisher, an eminent statistician of this
century, claimed that the early epidemio-
logic observations could not be interpreted
as proof of a cause-effect relationship,
arguing that one could not rule out that a
genetic factor both increased the propensi-
ty to smoke and the risk oflung cancer (2).
A key issue of criticism was that exact
knowledge of the mechanisms of tobacco
carcinogenesis was necessary to establish a
cause-effect relationship. Such criticism
was at the root of skepticism toward epi-
demiological evidence and its applications
in public health.
The investigation of mechanisms of
cancer induction by tobacco should be
reviewed in the light ofthe large amount of
epidemiological evidence that has been
produced in the last decades (1). In partic-
ular, molecular techniques in the epidemi-
ology of tobacco-related cancer have been
applied in making three general types of
measurement: 1) internal exposure, includ-
ing the dose at the presumed target tissue
(DNA); 2) early biological effects, particu-
larly mutations and cytogenetic damage,
likely to be predictive of cancer; and 3)
variations in individual susceptibility to
carcinogens, mainly via metabolic poly-
morphisms.
Biomarkers ofExposure in Smokers
Among the 3800 chemicals that have been
identified in tobacco smoke, a large num-
ber of biologically active compounds are
included. The most important chemical
families of carcinogens are polycyclic aro-
matic hydrocarbons, aromatic amines,
nitroso compounds (including nitro-
samines), volatile compounds such as ben-
zene, and radioelements such as polonium-
210. Some ofthese chemicals, in particular
aromatic amines and nitrosamines, are
potent carcinogens in animal systems,
where they induce tumors in several
organs. Also, exposure of animals (rats,
hamsters, mice, and rabbits) to whole
smoke or condensate induces tumors ofthe
respiratory tract or ofthe skin. The tobac-
co-specific nitrosamine NNK [4-methylni-
trosamino)- 1-(3-pyridyl)- 1-butanone]
exhibits organ specificity (respiratory) in
rodent tumor induction, although there is
some dependency on species and route of
administration (3).
Chemical compounds derived from
tobacco smoke have been measured in
biological specimens of smokers and non-
smokers. Considering only carcinogenic
compounds, tobacco-specific nitrosamine
adducts have been found to be higher in
the blood of smokers compared to non-
smokers (4). Adducts are reaction products
between chemical carcinogens and macro-
molecules. Among the class of respiratory
carcinogens known as polycyclic aromatic
hydrocarbons (PAHs), benzo[a]pyrene
forms DNA adducts in the lung that are
associated with smoking. Alexandrov et al.
(5) revealed the presence ofbenzo[a]pyrene
diol-epoxide-guanine adducts in lung sam-
ples from smokers; these adducts in the
guanine bases of DNA are in accordance
with the main type of mutations (G to T
transversions) found in the K-ras oncogene
and p53 tumor-suppressor gene. A corre-
spondence between smoke-associated DNA
adducts in vivo and DNA damage induced
by cigarette smoke condensate in vitro has
been found (6).
Tobacco smoke (particularly from air-
cured tobacco) contains significant
amounts of another class of carcinogens,
aromatic amines (7). Several lines of evi-
dence involving the measurement of
adducts indicate that aromatic amines are
relevant to bladder carcinogenesis in smok-
ers. Epidemiologic studies have suggested
that the type oftobacco associated with the
highest risk of bladder cancer (air-cured
tobacco) is also richer in arylamines (7),
and that smokers ofair-cured tobacco have
higher levels of4-aminobiphenyl-hemoglo-
bin adducts in their blood, compared to
smokers of flue-cured tobacco (8). Some
arylamines, including 4-aminobiphenyl
and 2-naphthylamine, are among the most
potent human bladder carcinogens.
The concentration of4-aminobiphenyl
-hemoglobin adducts in both smokers and
nonsmokers is modulated by the N-acetyla-
tion phenotype; i.e., it is higher in slow
acetylators who deactivate 4-amino-
biphenyl more slowly (8). Talaska et al. (9)
found that the administration of4-amino-
biphenyl to dogs resulted in the formation
of a main DNA adduct, N-(deoxyguano-
sin-8-yl)-4-aminobiphenyl, in bladder cells.
N-(deoxyguanosin-8-yl)-4-aminobiphenyl
was one of the main DNA adducts in the
bladder cancer biopsies ofsmoking subjects
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(10). These epidemiologic and experimen-
tal observations suggest that arylamines
such as 4-aminobiphenyl may be responsi-
ble for the excess risk ofbladder cancer in
smokers (8). About 50% of bladder can-
cers arising in men living in Western
countries is attributable to smoking (1).
A group ofchemicals that is also highly
relevant for the mechanisms oftobacco car-
cinogenesis is tobacco-specific nitrosamines.
Although it is unlikely that they play a role
in bladder cancer (11), nitrosamines have
been invoked to explain the excess of
esophageal cancer in smokers. Nitrosamines
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have an organ-specific activity for the
esophagus in experimental animals (12),
and metabolic activation ofthe tobacco-spe-
cific nitrosamine NNN has been observed
in cultured human esophageal cells (13).
Although tar delivery did not correlate with
the amounts of N'-nitrosonornicotine
(NNN) and NNK in mainstream smoke,
such nitrosamines are much more concen-
trated in air-cured tobacco than in flue-
cured tobacco. Cancers of the esophagus,
larynx, pharynx, and oral cavity are more
strongly associated with air-cured than
flue-cured tobacco smoking (14-16).
In the case ofother cancer sites associ-
ated with cigarette smoking, the demon-
stration ofelevated smoking-specific DNA
adducts strengthens the biologic plausibili-
ty of the association. For example, the
determination ofDNA adducts in the cer-
vical epithelium of smokers is relevant to
the alleged increased risk ofcervical cancer
(1X.
The measurement of biomarkers of
internal dose (adducts) has been applied
also to the study ofenvironmental tobacco
smoke exposure. For example, metabolites
of the nitrosamine NNK have been mea-
sured in the urine of five nonsmokers
experimentally exposed to environmental
tobacco smoke (18). Such evidence con-
cerning a tobacco-specific lung carcinogen
is relevant to the proposal that environ-
mental tobacco smoke can cause lung can-
cer. Also, protein adducts formed by car-
cinogenic aromatic amines have been mea-
sured in nonsmokers in relation to envi-
ronmental tobacco smoke exposure (19).
Several amines have been measured in
indoor air: a considerable concentration of
compounds like anilines and toluidine was
reported, even in buildings where smoking
was not allowed (20).
Mutations in Oncogenes or
Tumor-suppressor Genes
Proto-oncogenes are normal cellular genes
that, when activated as oncogenes, cause
alterations of growth and differentiation,
thus enhancing the probability ofneoplas-
tic transformation. Tumor-suppressor
genes are normal cellular genes that, when
inactivated, also cause alterations ofgrowth
and differentiation patterns (21).
Mutations in specific genes can be used
in molecular epidemiology as "finger-
prints" of specific exposures, as surrogate
endpoints ofcancer, or for the further sub-
typing of cancer to clarify causal relations
(22). Epidemiologic evidence suggests the
association between chemical exposure,
oncogene mutation, and cancer onset
(23-33). Investigations concerning the ras
oncogene family or the p53 tumor-sup-
pressor gene have considered the associa-
tion between lung cancer and tobacco
smoking. Results of these studies suggest
that the mutational spectrum oflung can-
cer depends on whether the person was a
smoker (23). For example, K-ras mutations
have been demonstrated as a feature of
non-small-cell lung carcinoma (NSCLC),
and have been found to be associated with
heavy smoking. In a study on smokers and
nonsmokers affected by lung adenocarci-
noma, K-ras mutations were found more
frequently in smokers [odds ratio (OR) =
5.3; 95% CI, 1.1-25] (24). All mutations
were in codon 12, mostly G to T transver-
sions, as in other investigations on lung
cancer (25). G to T transversions of ras
have also been shown in lung tumors
induced in mice with benzo[a]pyrene (26).
In a second study on 48 lung cancer
patients, K-rasmutations were found in 14
specimens (and in 12 out of21 adenocarci-
nomas) (27). Also in this case, the most
common types of mutations were G to T
transversions in codon 12. An association
with heavy smoking was found (OR = 4.9;
90% CI, 1.2-19.5) (27). However, it is
premature to draw firm conclusions; an
unexplained finding is that the alleged
smoking-associated mutation is most fre-
quent in the histologic type least associated
with smoking, at least in past studies.
Investigations concerning p53 involved
the association ofsmoking with carcinoma
of the head and neck (28), lung (29),
radon-associated lung cancer (30), and uri-
nary bladder cancer (31-33). Among
patients with cancer ofthe head and neck,
Field et al. found overexpression in 67%
(28); only 1 out of 7 nonsmokers showed
overexpression, versus 29/37 smokers (OR
= 22; CI, 3.5-135). Of a group of 10
patients who had given up smoking more
than 5 years before, 9 had elevated expres-
sion of p53. Suzuki and colleagues (29)
examined 30 non-small-cell carcinomas of
the lung and found p53 mutations in 14.
The mutations were mainly ofthe G to T
type and were closely associated with
smoking habits, with an estimated OR of
5.3 for smokers of20 cigarettes per day or
more, compared to nonsmokers.
With regard to bladder cancer, differ-
ent p53 mutations have been observed in
Japanese subjects with urothelial cancer
(associated with cigarette smoking) (31)
and among Egyptians (associated with
schistosomiasis) (32). In one study, the
overexpression of p53 in bladder cancer
has been related to the number of ciga-
rettes smoked: the relative risk of nuclear
overexpression increased up to 8.4 for
those who smoked more than 2 packs per
day (33).
Methodologic issues concerning this
type of study should be considered thor-
oughly. It is critical to distinguish between
mutations that are related to specific expo-
sures (mutational spectra) and are an inte-
gral step in the carcinogenic process and
findings that are epiphenomena or simply
related to tumor progression. It is probably
premature to conclude that ras or p53
genes are causally involved in the mecha-
nism of tobacco carcinogenesis, partly
because we lack longitudinal evidence on
the time sequence of tobacco smoking,
gene mutations, and cancer onset. Among
the issues that require clarification, one is
the possibility that various studies show
different mutational frequencies because of
a bias in the selection ofpatients at various
stages of development in tumor progres-
sion (34). Cells showing p53 mutations or
overexpression are selected as a conse-
quence ofproliferative advantage and clon-
al expansion; therefore, it is not obvious
that the molecular events directly reflect
the effect of specific exposures. An even
more radical view is that mutations are the
expression ofreplicative errors with limited
biological significance and that cancer phe-
notypes result from aberrant patterns of
normal gene expression (35).
IndividualSusceptibility and
Genetic-Environmental Interactions
Genetic susceptibility to lung cancer has
been suggested by different types of inves-
tigations. Excess lung cancer mortality was
found among relatives of lung cancer
patients after allowing for covariates. A dif-
ficulty with these types of studies is ade-
quately adjusting for age at initiation of
smoking, passive smoking, and "familial"
but nongenetic exposures. However, the
evidence suggests that smoking and family
history are separate risk factors (thus falsi-
fying Fisher's hypothesis) (36). In three
studies, relatives of cases had an OR of
2-2.5 for mortality from lung cancer com-
pared with relatives of healthy controls,
after controlling for smoking (37).
According to segregation analysis, genetic
transmission was attributed to a single
codominant locus. Also, investigations of
twins show that monozygotic twins discor-
dant for smoking behavior have clearly dif-
ferent risks of lung cancer, which argues
against Fisher's hypothesis (38,39). In the
Swedish Twin Registry, based on more
than 12,000 twin members, the relative
risk for lung cancer among male smokers
was 19.7; among monozygotic men, the
relative risk for smoking twins compared
to nonsmoking co-twins was 7.0; among
dizygotic twins, the estimate was 17.0.
These data, consistent with a more recent
study from an American World War II
Veterans Twin Registry (40), suggest that
smoking, and not genetic make-up, is the
chiefdeterminant oflung cancer.
Additional evidence has been provided
by the study of metabolic polymorphisms
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(i.e., the different ability, based on the
individual genetic make-up, to metabolize
chemical carcinogens). Traditional "mono-
genic" susceptibility to cancer is related to
rare diseases or small subgroups offrequent
diseases (like BRCA1 in familial breast can-
cer) and involves rare mutations identified
through linkage analysis. "Polygenic" sus-
ceptibility involves frequent genetic poly-
morphisms, entails a low-to-medium eleva-
tion ofthe risk for frequent diseases, and is
identified through epidemiologic case-
control studies. One example ofmetabolic
susceptibility based on genetic polymor-
phism is the CYP2D6 (debrisoquine) phe-
notype, which has been extensively stud-
ied. About 6-8% of whites are "poor"
debrisoquine metabolizers (i.e., they slowly
deactivate the drug). In a few investiga-
tions, slow debrisoquine metabolizers have
been suggested to have a reduced risk of
lung cancer compared with extensive
metabolizers (37), although not all investi-
gations agree. According to a pooled analy-
sis, a weakly positive relative risk of 2.3
(95% CI, 1.6-3.4) was found for the risk
of lung cancer in fast metabolizers (37).
Studies based on the determination of the
genotype, rather than the phenotype,
showed discordant results, with two studies
reporting an association between the exten-
sive metabolizer genotype and lung cancer
and one showing the opposite relationship
(41). While the precise mechanism for the
effect of the CYP2D6 polymorphism is
uncertain, the possibilities include activa-
tion of the tobacco-specific nitrosamine
NNK, or the recently reported role for
CYP2D6 in nicotine metabolism (42).
InJapanese studies, but not in Western
studies, the CYPlAI and glutathione S-
transferase (GST) polymorphisms have
been shown to be associated with lung can-
cer risk and, in the latter case, bladder can-
cer risk. CYPlAI metabolizes PAHs such
as benzo[a]pyrene to reactive electrophilic
epoxide compounds, which can form
DNA adducts. In the study by Nakachi et
al. (43), a very strong association was
found between lung cancer and the pres-
ence of both the "null" GST#1 genotype
and the mutant "val/val" CYPlAI geno-
type. The relative risk was 41.0 (95% CI,
9-194), suggesting that the combination
of polymorphisms may increase the indi-
vidual susceptibility enormously (43).
While the association of CYPlAI with
lung cancer has not been confirmed in a
Finnish investigation (44), the "null"
GST1u genotype or its phenotypic expres-
sion has been consistently associated with
increased risk of cancers of the lung and
the bladder (45-47). In some investiga-
tions, relative risks for cancer of the lung
were in the order of0.2-0.3 in those with
"high" GSTu1 activity, suggesting strong
protection (45,46). In one study, the pres-
ence of PAH-DNA adducts in the lung
was strongly related to the null GSTu1
genotype (48).
In the case ofbladder cancer, extensive
literature has been published on the N-
acetyltransferase (NAT) polymorphism
(49). NAT is a noninducible enzyme that
deactivates carcinogenic aromatic amines
such as 2-naphthylamine and 4-amino-
biphenyl. The frequency ofthe slow-acety-
lator genotype is about 50% in white pop-
ulations. Slow acetylators exposed to aro-
matic amines have been reported to have
an increased risk of bladder cancer and
higher levels of 4-aminobiphenyl adducts
(50,51). The study of metabolic polymor-
phisms, which is rapidly developing,
requires a thorough evaluation in terms of
studydesign and causal assessment (52).
Multistep Nature ofCarcinogenesis
After Berenblum proposed that carcinogen-
esis consists of an early stage called initia-
tion and a late stage called promotion (53),
several lines of evidence supporting the
multistep nature of cancer have been pro-
vided. Intermediate stages ofcancer can be
identified by histological and biochemical
techniques, and preneoplastic lesions
progress to neoplastic with varying degrees
ofprobability. Studies ofexperimental car-
cinogenesis established that different chem-
icals affect different stages in the carcino-
genic process, and cell transformation stud-
ies revealed that different phenotypic prop-
erties of tumor cells are acquired by a pro-
gressive process. Also, the neoplastic con-
version of normal cells requires multiple
cooperative genes. Although experimentally
induced and spontaneous tumors frequent-
lyshow mutations ofspecific genes, e.g., ras
or p53, many ofthem do not contain such
mutations. With the possible exception of
the retinoblastoma gene, mutations in the
hitherto identified oncogenes or tumor-
suppressor genes do not seem to be suffi-
cient to induce cancer. In skin papillomas
induced in mice with PAHs such as
dimethylbenzanthracene (a constituent of
tobacco smoke) a high frequency of H-ras
mutations (A to T transversions) was
detected. These mutations were heterozy-
gous and were interpreted as early lesions
involved in tumor initiation; H-ras
homozygous mutations were identified in
the later stage ofprogression, leading from
papillomas to carcinomas (54). Unlike early
papillomas, later lesions are dysplastic and
aneuploid with nonrandom chromosomal
changes and progress to carcinomas with
additional karyotypic abnormalities. A high
frequency of H-ras mutations has been
found also in esophageal tumors induced
experimentallywith N-nitroso compounds.
The studies by Auerbach et al. (55) on
autopsy specimens from the bronchi
showed changes in the epithelium that
were clearly associated with smoking
habits, including basal-cell hyperplasia, loss
ofcilia, and occurrence ofcells with atypi-
cal nuclei. The frequency of such changes
was higher in smokers than in nonsmokers
and increased with the amount of smok-
ing, after adjustment for age.
Epidemiology can contribute to the
elucidation ofmechanisms ofcarcinogene-
sis (early or late stages of action) through
the study oftiming ofexposure and cancer
onset. In the case of lung cancer, a large
amount of literature has been published
that dearly suggests that quitting smoking
is followed by a "freezing" ofthe risk until
the risk ofquitters relative to that of non-
smokers (i.e., the relative risk) approaches
the value of one (1,56). Also, age at start-
ing smoking is an independent determi-
nant of the risk of lung cancer because an
earlier age at start is associated with a con-
siderably higher incidence ofcancer (1,57.
Similar data have been published for blad-
der cancer. An interesting observation was
made comparing the effects of age at start
and time since cessation of exposure
among smokers of air-cured tobacco and
among workers heavily exposed to carcino-
genic aromatic amines (benzidine and 2-
naphthylamine). The trends were almost
overlapping for the two exposures: in both
cases, after 10 years or more since cessation
ofexposure, the relative risk ofcancer was
reduced by at least 75%, while the relative
risk approximately halved when exposure
started after age 25, compared to earlier
age at start (10). These observations fur-
ther suggest that the bladder carcinogenici-
ty of air-cured tobacco may be attributed
to arylamines.
Conclusions
Tobacco smoke contains many mutagenic
and carcinogenic chemicals. Both whole
tobacco smoke and extracts induced
tumors in experimental animals. Work
with carcinogen-macromolecule adducts is
important because these compounds pro-
vide evidence for the specific action of
exposures in the carcinogenic process. A
general trend in molecular epidemiology
studies is the increasing evidence that point
mutations in tumor-suppressor genes and
oncogenes may be specific both for the
type oftumor and for the critical environ-
mental exposure. The consistency among
investigations on oncogene/tumor-suppres-
sor gene mutations in lung cancer (and
other tobacco-related cancers) in smokers
is suggestive, although we still lack infor-
mation about the time sequence between
exposure, gene mutation, and cancer onset.
The epidemiological study of time vari-
ables (age at start of smoking, time since
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cessation, age at cancer onset) provides
suggestions about an early/late action of
carcinogens. In particular, published inves-
tigations suggest that for lung and bladder
cancer, smoking acts both at an early stage
and a late stage of the process. In the case
of bladder cancer, the similarity between
smoking and heavy occupational exposure
to carcinogenic aromatic amines is particu-
larly suggestive, as far as timing ofexposure
is concerned.
Highlights of current work that
deserves emphasis include investigations on
the lungs of smokers revealing that they
contain benzo[a]pyrene diol-epoxide-gua-
nine DNA adducts, which are in accor-
dance with the type ofmutations found in
K-ras or p53 genes (G to T transversions).
K-ras and p53 mutations have been found
more frequently among smokers than
among nonsmokers affected by lung can-
cer. DNA in human exfoliated bladder
cells show a derivative of4-aminobiphenyl
as a main adduct; there is an association
between smoking habits (amount and type
of tobacco) and the levels of both DNA
adducts and hemoglobin adducts formed
by aromatic amines.
Fisher's hypothesis that genetic predis-
position both induces smoking habits and
increases the risk of lung cancer has been
refuted on the basis of twin studies.
However, there is evidence of genetic sus-
ceptibility to lung cancer, independent
from smoking habits, attributed to a single
codominant locus. In addition, the ability
to metabolize tobacco carcinogens, such as
tobacco-specific nitrosamines and 4-
aminobiphenyl, seems to depend on a
genetically based metabolic polymorphism
(43). At least in such cases, genetic suscep-
tibility does not seem to be a risk factor per
se, but, rather, an effect modifier of the
exposure to carcinogens. Meanwhile, pub-
lic health efforts should focus squarely on
the central cause for preventable cancer in
the Western world, limiting tobacco use.
The example of smoking and cancer is
encouraging for molecular epidemiology,
but issues concerning the validation ofbio-
markers and the design of studies should
be addressed. Interesting developments
have been proposed concerning both
aspects. For example, Taioli et al. (58) have
tested a model for the validation of bio-
markers, which provides information on
intersubject, intrasubject, and analytical
measurement variability. Begg and Zhang
(59) have proposed specific statistical tools
for the analysis of molecular epidemiology
studies using case-series like those concern-
ing tumor-suppressor gene mutations.
More generally, methodological issues
should be clarified before straightforward
causal inferences are drawn (60).
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T he American Health Foundation is an independent biomedical research organization whose mission is
research on specific environmental, nutritional and exogenous factors causing cancer, cardiovascular dis-
ease, certain genetic diseases and aging. Synthelabo Pharmaceuticals is a private pharmaceutical compa-
ny which ranks number five in France. In addition to conducting safety studies, one ofits primary concerns is
education in drug safety. So, with this common interest, the International Course on the Safety Assessment of
Pharmaceuticals was started in 1992.
The Course is designed for veterinarians, physicians, pharmacists and scientists of the pharmaceutical indus-
try in charge of nonclinical studies and those responsible for the registration of new drugs. Participants will
receive the scientific information necessary for a good comprehension ofthe results ofnonclinical safety stud-
ies. Toxicologists and toxicologic pathologists may also benefit from this course by updating their knowledge.
The Course will be held on May 7-12, 1995 at the Hilton Inn in Tarrytown, New York, which is approximate-
ly 30 miles north ofNew York City. For a brochure and registration card please contact:
Janet Marino
American Health Foundation
1 Dana Road, Valhalla, NY 10595
tel. 914/789-7140 orfax: 914/592-6317.
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